Imeglimin
 | |
| Names | |
|---|---|
| IUPAC name
(2S)-N6,N6,2-Trimethyl-1,2-dihydro-1,3,5-triazine-4,6-diamine | |
| Identifiers | |
| 775351-65-0 | |
| ChemSpider | 26232690 |
| Jmol interactive 3D | Image |
| |
| |
| Properties | |
| C6H13N5 | |
| Molar mass | 155.21 g·mol−1 |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Imeglimin is an experimental drug being developed as an oral anti-diabetic. It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It will be the first of a new class of anti-diabetic if it is approved.
Imeglimin is in development (completed phase IIb clinical trials) for use both as monotherapy and in combination with other type-2 diabetes treatments.[1][2]
Various research protocols are being known through various scientists. Early studies showed that imeglimin is as effective as metformin in regulating glycaemic control.[3]
References
- ↑ "Diabetes Therapy Company Poxel Raises $21M in Series A Financing". Genetic Engineering & Biotechnology News. Jul 8, 2010.
- ↑ http://www.reuters.com/article/2013/03/07/idUSnHUGGg5Jta+1e4+ONE20130307
- ↑ http://www.omicsonline.org/2155-6156/2155-6156-2-126.php#1
This article is issued from Wikipedia - version of the Tuesday, July 07, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.